Approximately one-third of IBD patients will lose endoscopic response to biologic agents.21 As such, TDM may assist practitioners in both preventing and addressing loss of response to therapy.22 Despite demonstrated efficacy in anti-TNF agents,10 the utility of UST TDM remains a controversial subject. Here, TNF is linked to inflammatory bowel disease.